| Literature DB >> 21892159 |
Priscila P Zenatti1, Daniel Ribeiro, Wenqing Li, Linda Zuurbier, Milene C Silva, Maddalena Paganin, Julia Tritapoe, Julie A Hixon, André B Silveira, Bruno A Cardoso, Leonor M Sarmento, Nádia Correia, Maria L Toribio, Jörg Kobarg, Martin Horstmann, Rob Pieters, Silvia R Brandalise, Adolfo A Ferrando, Jules P Meijerink, Scott K Durum, J Andrés Yunes, João T Barata.
Abstract
Interleukin 7 (IL-7) and its receptor, formed by IL-7Rα (encoded by IL7R) and γc, are essential for normal T-cell development and homeostasis. Here we show that IL7R is an oncogene mutated in T-cell acute lymphoblastic leukemia (T-ALL). We find that 9% of individuals with T-ALL have somatic gain-of-function IL7R exon 6 mutations. In most cases, these IL7R mutations introduce an unpaired cysteine in the extracellular juxtamembrane-transmembrane region and promote de novo formation of intermolecular disulfide bonds between mutant IL-7Rα subunits, thereby driving constitutive signaling via JAK1 and independently of IL-7, γc or JAK3. IL7R mutations induce a gene expression profile partially resembling that provoked by IL-7 and are enriched in the T-ALL subgroup comprising TLX3 rearranged and HOXA deregulated cases. Notably, IL7R mutations promote cell transformation and tumor formation. Overall, our findings indicate that IL7R mutational activation is involved in human T-cell leukemogenesis, paving the way for therapeutic targeting of IL-7R-mediated signaling in T-ALL.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21892159 PMCID: PMC7424552 DOI: 10.1038/ng.924
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330